The Drug Science Podcast

In this episode, Prof Nutt meets with German author Norman Ohler as he speaks about his new book “Tripped” which addresses drug use in post-Nazi Germany. Ohler shares how a secret history held back therapeutic research of psychedelic drugs for decades and eventually Nazi policies became part of the foundation of America’s War on Drugs. Ohler discusses theories as to why substances have been omitted from certain parts of history. This episode delves into deep debates regarding the weaponisation of substances within war environments, touching upon the CIA’s attempts to weaponise psychedelics such as LSD in their MK Ultra experiments. MethamphetamineAmphetamineBlitzkriegBlitzed – drugs in nazi Germany bookLSDTrippedCocaineAlbert HofmannPsychedelics David NuttBecome a drug science community member  ★ Support this podcast ★

On the 100th Episode of the Drug Science podcast, Prof David Nutt meets with Dr James Rucker to celebrate the 100th anniversary of Maudsley Hospital. James shares his experiences as one of the first clinicians in a psychedelic study hosted by David Nutt before explaining his own personal journey into psychedelic research. Starting from a PhD in Genetics, James’ interest shifted, becoming increasingly interested in psychiatry and discusses his research into psilocybin regarding both its optimum dosage as well as its effectiveness in treatment resistant depression. DepressionMaudsley HospitalMaudsley Hospital Psychedelic ResearchNIHRCompass pathwaysPsilocybinMagic medicine documentaryMdma Dmt KetamineMAPSSupport the Podcast ★ Support this podcast ★

In this episode, we meet with Jane Slater, co-founder of Anyone’s Child and Anne Marie, a mother who tragically lost her child, Martha, to an accidental overdose. Anne and Jane discuss the consequences of drug policy failures and the need for safe drug use education, drawing in on Anne’s personal journey. She discusses the pain of losing a loved one to a preventable drug related death and how this pain led to the start of Anyone's Child - creating a voice for those who have been directly impacted by drug policy failures and are now calling for the legal control and regulation of the drug market.Anyone's childTransform drugsAnyone's Child Get involvedRelease Harm Reduction AdviceDrug informationEcstasyHeroinOverdose prevention centresThe loopHow to regulate psychedelics bookGood Morning Britain Dealing with griefUNGAS 2016 ★ Support this podcast ★

In this week's episode, we feature John Marks, an Addiction Psychologist who spearheaded the Merseyside experiment in northwest England from 1982 to 1995. Throughout this 13-year period, Marks fearlessly operated clinics in Liverpool, basing his practice on the long-term maintenance prescribing of opiates to opiate users.The high media profile of his work, set against the backdrop of febrile local politics in Liverpool, brought immense political pressure. This pressure eventually led to the closure of the clinics.Tune in to this episode as John Marks shares his first-hand experiences, recounting the challenges, triumphs, and controversies surrounding his work on the experiment. He provides insights into the intricacies of the UK's drug laws and discusses their impact on his experiment.Alcohol heroinMisuse of drugs act 1971The ‘Classic paper’ – The North Wind and the SunAccidy, Addiction and the ProhibitionElectroencephalographic Correlates of PsychometryEEG and PsychometryThe Cartesian Bridge: On the Psychology of Consciousness and the Psychopathology of Addiction and SchizophreniaNorth wind and the sunCounty linesSupport the podcast ★ Support this podcast ★

In this episode, we meet with Patrick Cox, a fashion designer with a background collaborating with Vivienne Westwood. Patrick shares his personal journey from his lifestyle in fashion, led to confronting deep-seated intergenerational trauma. Patrick opens up about undertaking the highly secretive Hoffman Process, and the transformative impact this had on him. From there, he further recounts his journey through the healing use of psychedelics, emphasising the transformative power of ego death. Patrick highlights how this journey led to him becoming a 5-MeO facilitator, and guiding others through these healing experiences.5-MEOVivienne WestwoodThe Hoffman processChristopher HitchensLSDCannabisAyahuasca Ego DeathHermet phaseSupport the Podcast ★ Support this podcast ★

In this episode, David Nutt meets with Evgeny Lebedev, owner of the Independent and Evening Standard newspaper. Lebedev shares his transformative journey during his first Ayahuasca ceremony in Costa Rica. Throughout the episode, Lebedev not only shares insight into the ceremony's practices but also describes each personal ayahuasca experience and the themes that tied them together. He highlights his revelations resulting from the ceremony and they discuss the potential of psychedelics within healing practices.  AyahuascaPsilocybinLSDDMTSmall PharmaMedical CannabisVietnam hippiesOCDDepressionDr Gabor MateSupport the podcast ★ Support this podcast ★

In the last episode of our live series, David meets with Sorcha as she explains her ongoing research into using low dose psilocybin in treating OCD. She discusses the pre-existing treatment paradigms for OCD and highlights the potential benefits of Psilocybin assisted psychotherapy in future treatment. She overviews her current study and the theories behind it.   SchizophreniaOCDPsilocybinSSRI              NeuroplasticityThe Mushroom CureSupport the Podcast ★ Support this podcast ★

Tomasso discusses his journey on how he became interested in neuroscience and how that lead to him becoming involved with the UK's leading Psychedelic Research Centre. He discusses the potential of psychedelics in promoting positive sexual wellbeing and healthy relationships. He discusses research into the advantages of using psilocybin as an alternative to SSRI’s as well as the potential uses of MDMA in promoting communication within relationships.   DMT5-MEO DMTPsilocybinMDMAMAPSTreatment resistant PTSDOxytocinSupport the Podcast ★ Support this podcast ★

David talks to Hannah, a 3rd year PhD student as she discusses her research into using psychedelics to treat eating disorders. She highlights how following personal experiences she came to find current treatment methods for anorexia were not sufficient and instead began conducting her own research with Imperial College London to investigate psilocybin-assisted psychotherapy to treat eating disorders. Hannah explains the theories underlying this research as well as the neuroplasticity following from psilocybin which may increase its effectiveness in mental health treatment AnorexiaEating disorder SerotoninayahuascaPsilocybinNeuroplasticityBecome a Drug Science Community Member ★ Support this podcast ★

In the first of our LIVE Psilocybin Series, David Nutt speaks to Rayyan Zafar a final year PhD student at Imperial College London.  Rayyan discusses his interest of the connection between the mind and the brain and how it led to his research into using psychedelics to treat addiction. Rayyan delves into various behavioural and neurochemical theories into why dependency occurs and highlights neuroimaging studies which indicate these varied reactions. He further goes on to discuss his current research in using psychedelics to treat addiction and why this treatment is proven to be so successful. AddictionMDMACocaineLSDPsilocybin KetamineNeurotransmittersDopamineCompass PathwaysBill Wilson AA PsychedelicsBecome a drug science community member ★ Support this podcast ★

In this episode, Josh Hardman, the founder of Psychedelic Alpha, explores the multitude of challenges currently being encountered by the psychedelic industry. He engages in discussions regarding the progress of decriminalisation and legalisation initiatives, upcoming clinical trial milestones, and delves into the current state and the potential evolution of the Psychedelic industry. Psychedelic AlphaMDMAPsilocybinGHBCannabisDMTPsychoplastogensMAPSCOMPASS PathwaysNICEOregon Psilocybin Services ★ Support this podcast ★

In this episode, Prof Jo Neill and Dr Hannah Thurgur sit down with Dustin Robinson, the visionary founding partner of Mr. Cannabis Law and a co-founder of Mr. Psychedelics Law. These law firms possess the expertise needed to navigate the intricate and strictly regulated realms of cannabis and psychedelics, addressing a wide range of legal and business challenges within these unique industries.Their discussion covers a range of thought-provoking topics, including US drug policy and reform, the intricate relationship between mental health and these substances, issues around integration of indigenous psychedelics into Western medicine, and the challenges surrounding research funding. Mr Cannabis LawMr Psychedelic LawAdventure Capital FirmKetaminePsilocybinMDMADMTPTSDKetamineTelehealthSmall PharmaMAPS MDMA TrialCompass PathwaysDecriminalise NatureThe Beckley Foundation AwaknSupport the Podcast  ★ Support this podcast ★

Recorded live from the launch event of David Nutt's latest book, "Psychedelics: The Revolutionary Drugs That Could Change Your Life – a guide from the expert," in this episode Dr. David Erritzoee and David Nutt engage in a discussion about Psychedelics. During the conversation, David Nutt provides valuable insights into the research that initially ignited his interest in Psychedelics and narrates his career journey from chairing the Advisory Council on the Misuse of Drugs to becoming a co-chair of Drug Science. Psychedelics: The revolutionary drugs that could change your life – a guide from the expertSentiaPsilocybinMDMAAntidepressants DepressionLSD DMT AyahuascaAmphetamineNitrous OxideKetamineCannabisEquasy — An overlooked addiction with implications for the current debate on drug harmsAustralia using MDMA and Psilocybin as MedicineSupport the podcast ★ Support this podcast ★

In this episode, Mike Jay explores the contents of his latest book titled "Psychonaut," which offers a thought-provoking and unique account of the scientists, writers, artists, and philosophers who engaged in drug exploration to uncover the enigmatic realms of the mind. The podcast delves into the historical perspective of psychedelics, shedding light on the evolving societal perceptions of these substances. Moreover, it seeks to rediscover a forgotten intellectual legacy of drug experimentation that contributed to the development of psychology, the exploration of the unconscious, and the rise of modernism. The High Society book Mescaline BookPsychonauts BookBrave New World BookThe Doors of Perception BookCocaine Papers Sigmund Freud AlcoholCocaineNitrous OxideCannabisLSDAddictionSupport the podcast ★ Support this podcast ★

In this episode, Meg Spriggs shares her firsthand experience dealing with the challenges mental health while pursuing her studies in academia. She candidly talks about the difficulties she faced with anorexia and mood disorders which led to her investigating the potential of psilocybin for treating Anorexia Nervosa. During the discussion, Meg reveals the shame she felt was associated with various mental health conditions and the consecutive impact this had on her; emphasising the significance of open communication when it comes to mental health, stressing the need for more dialogue and understanding in both the workforce and academia. Additionally, she underscores the importance of prioritising overall wellbeing within these environments. Anorexia NervosaPsilocybinAntidepressantsBeat Eating Disorder SupportSupport the podcastMeg’s Writing Support Meg’s writing   ★ Support this podcast ★

In this episode, Jo Neill, and Hannah Thurgur are joined by Danny Ahmed, a highly experienced Registered Mental Health Nurse and Integrated Psychotherapist with over two decades of expertise. Together, they delve into a comprehensive discussion on a variety of harm reduction techniques. Throughout the episode, Danny shares his wealth of insights into the complex world of harm reduction. The conversation spans a broad spectrum of topics, including drug consumption rooms, the notion of ‘recovery’ and women who use drugs amongst much more. Danny offers an enlightening look into the multifaceted world of harm reduction. His expertise not only illuminates effective strategies but also underscores the importance of employing compassionate and empathetic approaches when supporting individuals on their path to well-being. Harm reductionNaloxoneMDMAHeroin CocaineAlcoholBenzodiazapinesMethadoneFentanylBuprenorphineSynthetic opioidsOverdose prevention centresRIOTT trials Project ADDERAlcoholics AnonymousPolydrug useNaloxoneOrder NaloxoneBuddyup AppSupport the Podcast ★ Support this podcast ★

In this episode, Professr Valerie Curran, discusses the psychological effects of drugs that act on the human brain. Valerie Curren holds the position of Professorial Fellow in the Neuroscience of Addiction and Mental Health Program at ACU's Healthy Brain and Mind Research Centre. She has an esteemed background as an Emeritus Professor of Psychopharmacology at University College London (UCL), having established the UCL Clinical Psychopharmacology Unit in 1996. Furthermore, she is a founding member of the charity Drug Science and serves as an advisor to the UK All Party Parliamentary Group on Drug Policy Reform.Tune in to learn about her latest research into the short- and long-term effects of psychoactive drugs on mental health, cognition, memory and the brain as well as how CBD combined with psychological therapy may aid the treatment of cannabis use disorder.BenzosMDMAAlcoholCannabisCBDTHCKetamineMDMA midweek blues paper – in journal Addiction (mid 90s) Inappropriate benzodiazepine use in elderly patients and its reduction Combined and individual effects of CBD and THC on memoryDavid Nutt and Psilocybin in Australia  Cannabis potencyCBD treating clinical psychosisCBD in treating cannabis use disorderProject 2021Medical cannabis reducing opiate useJon snow takes cannabis Endocannabinoid systemSupport the podcast ★ Support this podcast ★

Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and Scientific Officer at Small Pharma Labs. Dr. Routledge takes us on a journey through her remarkable career path that ultimately led her to work at Small Pharma. With a wealth of experience in both preclinical and clinical settings, she has delved into psychiatric and neurological indications, honing her expertise in understanding and treating mental health disorders.In this conversation, Dr. Carol Routledge draws upon her extensive clinical and psychedelic research background to shed light on the latest developments in DMT research and psychedelic integration therapy. With her profound insights, we explore the potential of these groundbreaking approaches to become formal medicines, revolutionizing the field of mental health treatment.Tune in as Dr. Carol Routledge shares her passion for advancing mental health treatments through innovative research. DMT DepressionSerotoninNor adrenaline Small PharmaChris Timmermann - Human brain effects of DMT assessed via EEG-fMRICMC British technology group (BTG)SSRI Psychedelic experienceAlzheimers research uk  ★ Support this podcast ★

In this episode, Peter Hunt discusses the journey which led himself and his wife co-founding Mind Medicine in Australia. Mind Medicine work to alleviate the suffering and suicides caused by mental illness in Australia through expanding the treatment options available to medical practitioners and patients, particularly through the establishment of safe and effective psychedelic-assisted therapies.Delving into the heart of their mission, Peter Hunt explores the groundbreaking potential of psychedelic-assisted treatments in addressing a wide range of mental illnesses. Mind Medicine Australia's commitment to providing accessible and innovative therapies shines through every step of their path.Peter delves into a comprehensive discussion of the recent developments surrounding the rescheduling of Psilocybin in Australia, shedding light on both the obstacles faced and the triumphs achieved throughout the process.Trigger Warning: Sexual assault and rapeMind MedicineMDMAPsilocybinDepressionAlcoholAddictionPTSDChildhood abuseSSRI antidepressantsCovid-19AnorexiaTherapeutic goods administrationAustralia Psilocybin Rescheduling ★ Support this podcast ★

This weeks Podcast features Frédéric Destrebecq and Tadeusz Hawrot as they discuss the latest developments in research and clinical development with psychedelics in Europe.Frédéric Destrebecq is the Executive Director of the European Brain Council (EBC), a non-profit organization based in Brussels, Belgium. The EBC is a network of organizations and individuals dedicated to promoting brain research, raising awareness about brain disorders, and advocating for better policies and funding for brain-related issues at the European level. As the Executive Director, Frédéric Destrebecq leads the organization's efforts in advocating for brain research and policy development, facilitating collaborations, and coordinating initiatives to improve brain health and well-being across Europe.Tadeusz Hawrot is involved in the European federation of neurological associations and the founder and Executive Director of PAREA Science. The Psychedelic Access and Research European Alliance (PAREA) is a multistakeholder alliance bringing together organizations representing EU-wide patient advocacy groups, professional organizations, umbrella alliances, psychedelic foundations, and companies active in the field, advocating for implementing safe, effective and accessible psychedelic assisted therapies in Europe.Live Drug Science Podcast Recording in London  PAREA European Brain council European Federation of Neurological Associations The Value of Treatment Project Maps MDMA phase 3 trial Compass Pathways Small Pharma Politico Lancet Horizon MDMA Support the Podcast  ★ Support this podcast ★